טוען...
Biosimilar Insulin and Costs: What Can We Expect?
The costs for insulin treatment are high, and the steady increase in the number of patients with diabetes on insulin presents a true challenge to health care systems. Therefore, all measures to lower these costs are welcomed by patients, physicians, and health care providers. The market introduction...
שמור ב:
| הוצא לאור ב: | J Diabetes Sci Technol |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4773960/ https://ncbi.nlm.nih.gov/pubmed/26350722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296815605337 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|